Nature of Business and Significant Accounting Policies (Details Narrative)		3 Months Ended
	Apr. 20, 2023 USD ($)	Dec. 31, 2024 USD ($) Segment shares	Dec. 31, 2023 USD ($) shares
Schedule of Equity Method Investments [Line Items]
Revenue | $
Conversion of preferred shares		8,340,000
Number of operating segment | Segment		1
Series A Convertible Preferred Stock [Member]
Schedule of Equity Method Investments [Line Items]
Conversion of preferred shares		13,579,710	13,579,710
Series B Convertible Preferred Stock [Member]
Schedule of Equity Method Investments [Line Items]
Conversion of preferred shares		13,579,710	13,579,710
Convertible Notes Payable [Member]
Schedule of Equity Method Investments [Line Items]
Antidilutive securities earning per share		104,490,131	83,125,488
Share-Based Payment Arrangement, Option [Member]
Schedule of Equity Method Investments [Line Items]
Antidilutive securities earning per share		8,120,000	8,120,000
Warrant [Member]
Schedule of Equity Method Investments [Line Items]
Antidilutive securities earning per share		15,387,050	15,387,050
Discontinued Operations, Held-for-Sale [Member] | Purchase Agreement [Member]
Schedule of Equity Method Investments [Line Items]
Cash purchase price | $	$ 2,300,000